ProQR Therapeutics (NASDAQ:PRQR) Receives Consensus Rating of “Buy” from Analysts

ProQR Therapeutics (NASDAQ:PRQR) has earned a consensus recommendation of “Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $8.83.

A number of equities analysts recently weighed in on the stock. Raymond James raised shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from $6.00 to $14.00 in a report on Tuesday, October 29th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. StockNews.com lowered shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Chardan Capital reiterated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, Oppenheimer initiated coverage on ProQR Therapeutics in a research report on Friday. They issued an “outperform” rating and a $15.00 target price for the company.

Institutional Investors Weigh In On ProQR Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of PRQR. BNP Paribas Financial Markets raised its stake in shares of ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 7,300 shares during the period. OneDigital Investment Advisors LLC grew its holdings in ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares in the last quarter. Finally, Privium Fund Management B.V. increased its position in shares of ProQR Therapeutics by 0.9% during the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after buying an additional 51,663 shares during the period. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Trading Down 7.6 %

PRQR stock opened at $2.42 on Monday. The stock has a market cap of $197.67 million, a P/E ratio of -7.56 and a beta of 0.30. The stock’s fifty day simple moving average is $3.23 and its two-hundred day simple moving average is $2.52. ProQR Therapeutics has a 1-year low of $1.61 and a 1-year high of $4.62.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).